vs
Side-by-side financial comparison of American Well Corp (AMWL) and MESA LABORATORIES INC (MLAB). Click either name above to swap in a different company.
MESA LABORATORIES INC is the larger business by last-quarter revenue ($65.1M vs $55.3M, roughly 1.2× American Well Corp). MESA LABORATORIES INC runs the higher net margin — 5.6% vs -45.1%, a 50.6% gap on every dollar of revenue. On growth, MESA LABORATORIES INC posted the faster year-over-year revenue change (3.6% vs -22.1%). MESA LABORATORIES INC produced more free cash flow last quarter ($18.0M vs $-17.4M). Over the past eight quarters, MESA LABORATORIES INC's revenue compounded faster (5.1% CAGR vs -3.6%).
The American Tobacco Company was a tobacco company founded in 1890 by J. B. Duke through a merger between a number of U.S. tobacco manufacturers including Allen and Ginter, Goodwin & Company, and Kinney Brothers. The company was one of the original 12 members of the Dow Jones Industrial Average in 1896. The American Tobacco Company dominated the industry by acquiring the Lucky Strike Company and over 200 other rival firms. Federal Antitrust action begun in 1907 broke the company into several ...
Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.
AMWL vs MLAB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $55.3M | $65.1M |
| Net Profit | $-24.9M | $3.6M |
| Gross Margin | — | 64.2% |
| Operating Margin | -45.5% | 12.2% |
| Net Margin | -45.1% | 5.6% |
| Revenue YoY | -22.1% | 3.6% |
| Net Profit YoY | 41.6% | 316.6% |
| EPS (diluted) | $-1.53 | $0.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $55.3M | $65.1M | ||
| Q3 25 | $56.3M | $60.7M | ||
| Q2 25 | $70.9M | $59.5M | ||
| Q1 25 | $66.8M | $62.1M | ||
| Q4 24 | $71.0M | $62.8M | ||
| Q3 24 | $61.0M | $57.8M | ||
| Q2 24 | $62.8M | $58.2M | ||
| Q1 24 | $59.5M | $58.9M |
| Q4 25 | $-24.9M | $3.6M | ||
| Q3 25 | $-32.4M | $2.5M | ||
| Q2 25 | $-19.7M | $4.7M | ||
| Q1 25 | $-18.7M | $-7.1M | ||
| Q4 24 | $-42.7M | $-1.7M | ||
| Q3 24 | $-43.5M | $3.4M | ||
| Q2 24 | $-49.9M | $3.4M | ||
| Q1 24 | $-72.1M | $-254.6M |
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
| Q4 25 | -45.5% | 12.2% | ||
| Q3 25 | -52.1% | 7.8% | ||
| Q2 25 | -28.7% | 5.1% | ||
| Q1 25 | -45.5% | 2.4% | ||
| Q4 24 | -60.2% | 9.2% | ||
| Q3 24 | -77.6% | 6.1% | ||
| Q2 24 | -83.4% | 9.6% | ||
| Q1 24 | -126.1% | -460.6% |
| Q4 25 | -45.1% | 5.6% | ||
| Q3 25 | -57.5% | 4.1% | ||
| Q2 25 | -27.8% | 8.0% | ||
| Q1 25 | -28.0% | -11.4% | ||
| Q4 24 | -60.1% | -2.7% | ||
| Q3 24 | -71.2% | 5.9% | ||
| Q2 24 | -79.5% | 5.8% | ||
| Q1 24 | -121.1% | -432.2% |
| Q4 25 | $-1.53 | $0.65 | ||
| Q3 25 | $-2.00 | $0.45 | ||
| Q2 25 | $-1.24 | $0.85 | ||
| Q1 25 | $-1.19 | $-1.30 | ||
| Q4 24 | $-2.71 | $-0.31 | ||
| Q3 24 | $-2.87 | $0.63 | ||
| Q2 24 | $-3.36 | $0.62 | ||
| Q1 24 | $-4.94 | $-47.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $182.3M | $29.0M |
| Total DebtLower is stronger | — | $68.4M |
| Stockholders' EquityBook value | $235.6M | $186.7M |
| Total Assets | $323.8M | $434.8M |
| Debt / EquityLower = less leverage | — | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $182.3M | $29.0M | ||
| Q3 25 | $200.9M | $20.4M | ||
| Q2 25 | $219.1M | $21.3M | ||
| Q1 25 | $222.4M | $27.3M | ||
| Q4 24 | $228.3M | $27.3M | ||
| Q3 24 | $244.6M | $24.3M | ||
| Q2 24 | $276.9M | $28.5M | ||
| Q1 24 | $308.6M | $28.2M |
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
| Q4 25 | $235.6M | $186.7M | ||
| Q3 25 | $254.9M | $178.5M | ||
| Q2 25 | $282.6M | $172.5M | ||
| Q1 25 | $294.0M | $159.8M | ||
| Q4 24 | $304.8M | $155.2M | ||
| Q3 24 | $336.7M | $161.5M | ||
| Q2 24 | $363.9M | $150.7M | ||
| Q1 24 | $408.7M | $145.4M |
| Q4 25 | $323.8M | $434.8M | ||
| Q3 25 | $359.4M | $430.4M | ||
| Q2 25 | $388.7M | $435.7M | ||
| Q1 25 | $419.5M | $433.3M | ||
| Q4 24 | $436.0M | $433.3M | ||
| Q3 24 | $483.0M | $454.1M | ||
| Q2 24 | $507.8M | $440.4M | ||
| Q1 24 | $548.4M | $446.8M |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-17.4M | $18.8M |
| Free Cash FlowOCF − Capex | $-17.4M | $18.0M |
| FCF MarginFCF / Revenue | -31.4% | 27.7% |
| Capex IntensityCapex / Revenue | 0.0% | 1.1% |
| Cash ConversionOCF / Net Profit | — | 5.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | $37.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-17.4M | $18.8M | ||
| Q3 25 | $-18.8M | $8.2M | ||
| Q2 25 | $-4.7M | $1.9M | ||
| Q1 25 | $-25.1M | $12.7M | ||
| Q4 24 | $-13.4M | $18.1M | ||
| Q3 24 | $-32.4M | $5.3M | ||
| Q2 24 | $-21.8M | $10.7M | ||
| Q1 24 | $-59.8M | $12.9M |
| Q4 25 | $-17.4M | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | $-25.1M | $11.9M | ||
| Q4 24 | $-13.4M | $17.3M | ||
| Q3 24 | $-32.4M | $3.5M | ||
| Q2 24 | $-21.8M | $9.9M | ||
| Q1 24 | $-59.8M | $12.3M |
| Q4 25 | -31.4% | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | -37.6% | 19.2% | ||
| Q4 24 | -18.9% | 27.6% | ||
| Q3 24 | -53.0% | 6.0% | ||
| Q2 24 | -34.7% | 16.9% | ||
| Q1 24 | -100.5% | 21.0% |
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 1.3% | ||
| Q3 24 | 0.0% | 3.1% | ||
| Q2 24 | 0.0% | 1.5% | ||
| Q1 24 | 0.1% | 0.9% |
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMWL
| Platform Subscription | $28.8M | 52% |
| Visits | $23.7M | 43% |
| Others | $2.8M | 5% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
